Navigation Links
Macrocyclics presenta nuevos productos

DALLAS, 10 de enero de 2014 /PRNewswire/ -- Macrocyclics, Inc. (compañía de AREVA Med) anunció hoy la presentación de cuatro nuevos productos que ampliarán las aplicaciones de imágenes PET con cobre-64 y galio-68 usando plataformas quelatantes basadas en NOTA. Además, un nuevo conjugado de DOTA basado en serotonina ofrece el potencial para obtener imágenes de neurotransmisión serotoninérgicas utilizando un radioisótopo o con gadolinio mediante imágenes por resonancia magnética (MRI).


Visite para obtener más información.

Macrocyclics es el líder global en tecnologías de agentes quelatantes de alto desempeño para la medicina desde 1995. El equipo de Macrocyclics se dedica a proveer a los clientes agentes quelatantes y servicios tanto establecidos como innovadores para superar los desafíos de las imágenes moleculares y la medicina nuclear.

AREVA Med es una subsidiaria de AREVA que se especializa en el desarrollo de tratamientos innovadores para luchar contra el cáncer. AREVA Med creó nuevos procesos para producir plomo-212 (²¹²Pb) de alta pureza, un metal poco común que actualmente se encuentra en el centro de prometedoras investigaciones de medicina nuclear. En 2011, AREVA Med adquirió Macrocyclics, líder global en tecnología de agentes quelatantes de alto desempeño. AREVA Med también formó alianzas con socios científicos de primer nivel, como el Instituto Nacional del Cáncer (National Cancer Institute, NCI), la Universidad de Alabama en Birmingham (University of Alabama at Birmingham, UAB) y el Instituto Nacional Francés de Salud e Investigación Médica (French National Institute of Health and Medical Research, Inserm). En 2012, AREVA Med y Roche formaron una alianza estratégica para crear nuevos tratamientos avanzados de radioinmunoterapia alfa para atacar y matar ciertos tipos de células cancerígenas muy agresivas. Para obtener más información: o

Garry Kiefer
Teléfono: +1 972 250 2248
Fax: +1 972 250 2245

Alison Tise
Teléfono: +1 301 841 1673
Fax: +1 434 382 4250

FUENTE  Macrocyclics, Inc.

FUENTE Macrocyclics, Inc.

SOURCE Macrocyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Macrocyclics apresenta novos produtos
2. Macrocyclics introduces new products
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
5. Cepheid to Webcast Upcoming Financial Presentation
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
8. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
9. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):